VIVES is a multi-sector fund that invests in projects with a positive societal impact
Novadip was founded in 2013 as spin-off comany from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of professor and founder Dr. Denis Dufrane...
ATB Therapeutics is pioneering a new era in targeted therapies by developing next-generation Antibody-Drug Conjugates (ADCs) to transform cancer treatment. By combining cutting-edge biotechnology with...
The Tessares solution combines existing fixed and mobile networks to increase DSL speed with the speed of the 4G mobile network. This is called "Hybrid Internet", which immediately speeds up the speed...
Issam Doghri, Prof. at UCLouvain and co-founder of e-Xstream engineering:
"I developed a first version of a software (Digimat- for digital materials) and I was thinking about ways to make it...
Georges Caron, past CEO Keemotion:
"VIVES supported us at the beginning of the project when the risk was at its maximum. We needed time to test some hypotheses and confront academic research with the...
Torsten Mummenbrauer, CEO Exevir Bio:
"It has been great to partner early on with VIVES fund. VIVES fund helped us to finance the company, challenged us in our thinking to push us further in our...
Trial aims to enroll 12 children at eight sites in EU and US
Phase 3 trial in adult patients also planned for 2026 with focus on limb sparing associated with bone non-union (BNU)
Novadip aims to